Trump retweets COVID-19 video yanked by social media for pushing fake cure

President Donald Trump and his son, Donald Trump Jr., on Monday retweeted a viral video that was yanked by Facebook for pushing “false information about cures and treatments for COVID-19.”

The clip, which was originally posted by the right-wing news site Breitbart, featured four people who identified themselves as doctors speaking in front of the Supreme Court building. One was Stella Immanuel, who claims to be a physician in Houston, and said hydroxychloroquine, a malaria drug often touted by Trump, was a cure for COVID-19.

A number of scientific studies have determined that the drug was not only ineffective against the novel coronavirus but that it could cause fatal heart arrhythmia. According to the Centers for Disease Control and Prevention, at this time, there is no drug or therapy presently approved by the Food and Drug Administration to prevent or treat COVID-19.

Immanuel also said that people do not need to wear face masks and attacked “fake doctors” who “sound like a computer.” To avoid contracting coronavirus, the CDC advises wearing a face mask, limiting face-to-face contact with others and wearing gloves when cleaning and disinfecting or providing care for the sick.

Immanuel has an unusual background for a self-proclaimed COVID-19 expert. Information about her medical background is limited; however, she does serve as the head of Fire Power Ministries, which appears to be located in a Houston strip mall and promotes a baptism of fire program that offers “miracles, healings and deliverance.”

“If my page is not back up face book will be down in Jesus name,” she tweeted.

You don’t have a clue what you are talking about, this peer feviewed paper by a Yale University Professor of Epidemiology, with 300 previous peer-reviewed scientific in the field papers, DOES:

————————————————————————— Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis

Harvey A Risch
American Journal of Epidemiology, kwaa093,
Paper Source, Oxford University Press
Published: 27 May 2020

Abstract
More than 1.6 million Americans have been infected with SARS-CoV-2 and >10 times that number carry antibodies to it. High-risk patients presenting with progressing symptomatic disease have only hospitalization treatment with its high mortality. An outpatient treatment that prevents hospitalization is desperately needed. Two candidate medications have been widely discussed: remdesivir, and hydroxychloroquine+azithromycin. Remdesivir has shown mild effectiveness in hospitalized inpatients, but no trials have been registered in outpatients. Hydroxychloroquine+azithromycin has been widely misrepresented in both clinical reports and public media, and outpatient trials results are not expected until September. Early outpatient illness is very different than later hospitalized florid disease and the treatments differ. Evidence about use of hydroxychloroquine alone, or of hydroxychloroquine+azithromycin in inpatients, is irrelevant concerning efficacy of the pair in early high-risk outpatient disease. Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multicomorbidities, with estimated proportion diagnosed with cardiac arrhythmias attributable to the medications 47/100,000 users, of which estimated mortality is <20%, 9/100,000 users, compared to the 10,000 Americans now dying each week. These medications need to be widely available and promoted immediately for physicians to prescribe. Azithromycin, Covid-19, Doxycycline, Hydroxychloroquine, Remdesivir, SARS-CoV-2, Zinc

Topic: cardiac arrhythmia doxycycline azithromycin hydroxychloroquine ambulatory care services inpatients outpatients terminally ill antibodies mortality zinc older adult pandemics standard of care remdesivir sars-cov-2 covid-19

Issue Section: Special article

This content is only available as a PDF.

© The Author(s) 2020. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.